Summary of Inogen's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $95.1 million, a 3% year-over-year increase, driven by strong international growth and new product contributions.

U.S. Sales: $42.3 million, down 2% year-over-year, impacted by channel mix challenges in direct-to-consumer (DTC) sales.

International Sales: $41.3 million, up 15% year-over-year, marking the 10th consecutive quarter of double-digit growth.

Adjusted EBITDA: $2.4 million, a 15% improvement from the previous year.

Net Loss: GAAP net loss of $3.9 million, slightly improved from a loss of $4.2 million in Q2 2025.

Cash Position: Ended the quarter with $107 million in cash and cash equivalents, operating with no debt.

2Strategic Updates and Business Highlights

Product Innovation: Continued investment in new products, including the Voxi and Aurora, which received positive feedback and contributed over 100 basis points to revenue growth.

B2B Sales Channel: Increased investment in the B2B sales force, leading to a significant rise in U.S. customers through this channel.

International Expansion: Successful launches of the Rove 6 Portable Oxygen Concentrator in Canada and Brazil, with plans for further penetration in Eastern Europe and Latin America.

Clinical Advancements: Introduction of the QuOTE assessment tool to enhance patient management in long-term oxygen therapy, strengthening Inogen's scientific credibility.

3Forward Guidance and Outlook

Full-Year 2026 Revenue Guidance: Revised to $355 million to $361 million, reflecting a reduction from previous guidance due to market dynamics.

Adjusted EBITDA Guidance: Increased to approximately $4 million for the full year, indicating a 48% growth over 2025.

Third Quarter 2026 Revenue Expectation: Anticipated to be in line with Q3 2025 revenue of $92.4 million.

4Bad News, Challenges, or Points of Concern

DTC Sales Decline: Ongoing pressure in the DTC sales channel due to market shifts, with concerns about its sustainability and potential for continued erosion.

U.S. Rentals: Rental revenue decreased by 12% year-over-year, reflecting structural changes in how patients are prescribed oxygen therapy.

Inventory Management: Some international distributors are managing inventory levels, which may impact growth in the second half of the year.

Market Dynamics: The shift towards B2B sales is a tailwind for that channel but poses challenges for DTC, indicating a need for strategic adjustments.

5Notable Q&A Insights

Channel Dynamics: Management acknowledged the DTC channel's challenges but expressed confidence in stabilizing and potentially growing it through new product sales.

Gross Margin Improvement: Despite the mix shift towards B2B, gross margins improved due to cost-saving initiatives and lower warranty expenses.

Simeox Regulatory Progress: Updates on the Simeox product indicated ongoing enrollment in clinical trials, with expectations for regulatory clearance in China by year-end.

Patient and Provider Engagement: Emphasis on the importance of maintaining relationships with patients and healthcare providers to ensure brand loyalty and retention as the channel mix evolves. Overall, Inogen's Q2 2026 results reflect a mixed performance with solid international growth and product innovation, but challenges in the U.S. DTC channel and rental business raise concerns about future revenue stability. The company remains focused on strategic execution and long-term growth initiatives.